标题
Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
作者
关键词
Papillary renal cell cancer, MET, Foretinib
出版物
Current Oncology Reports
Volume 15, Issue 2, Pages 83-90
出版商
Springer Nature
发表日期
2013-02-13
DOI
10.1007/s11912-013-0299-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study
- (2012) Sandra Steffens et al. EUROPEAN JOURNAL OF CANCER
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
- (2012) Nizar M. Tannir et al. EUROPEAN UROLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage
- (2012) Kirk A. Keegan et al. JOURNAL OF UROLOGY
- Abstract A13: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184
- (2012) B. Sennino et al. MOLECULAR CANCER THERAPEUTICS
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma
- (2011) Ilya Tsimafeyeu et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
- (2011) Hung Huynh et al. ANGIOGENESIS
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
- (2011) C. Migliore et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis
- (2011) M. Zillhardt et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- Clinical and Pathological Features Associated With Prognosis in Patients With Papillary Renal Cell Carcinoma
- (2011) William R. Sukov et al. JOURNAL OF UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
- (2011) L. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Hereditary kidney cancer
- (2010) W. Marston Linehan et al. CANCER
- Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma
- (2010) Alessandro Antonelli et al. CANCER GENETICS AND CYTOGENETICS
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
- (2010) Aung Naing et al. INVESTIGATIONAL NEW DRUGS
- Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
- (2010) Ana M. Molina et al. INVESTIGATIONAL NEW DRUGS
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and External Validation of a Nomogram Predicting Disease Specific Survival After Nephrectomy for Papillary Renal Cell Carcinoma
- (2010) Tobias Klatte et al. JOURNAL OF UROLOGY
- Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
- (2010) Bradley C. Leibovich et al. JOURNAL OF UROLOGY
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
- (2009) T. Klatte et al. CLINICAL CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma
- (2009) Kathryn A. Bylow et al. Clinical Genitourinary Cancer
- Is there a Role of the Histologic Subtypes of Papillary Renal Cell Carcinoma as a Prognostic Factor?
- (2009) J. H. Ku et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
- (2009) Michael S. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype
- (2009) I Balint et al. JOURNAL OF CLINICAL PATHOLOGY
- Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
- (2009) Janice P. Dutcher et al. MEDICAL ONCOLOGY
- Prognostic factors in a prospective series of papillary renal cell carcinoma
- (2008) Paolo Gontero et al. BJU INTERNATIONAL
- A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study
- (2008) Umberto Capitanio et al. BJU INTERNATIONAL
- Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma
- (2008) Vitaly Margulis et al. CANCER
- Molecular cancer therapy: Can our expectation be MET?
- (2008) Cristina Migliore et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More